Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
+ w' g: M0 v# T0 I% |8 a1 A& G
b& H2 x$ S( A7 e2 z& O. q2 o1 b" ]! ~% K
Sub-category:7 @# ^$ F5 @ g3 R
Molecular Targets
( {1 z$ G) i( y$ q* `8 f" J" u p0 i' q8 {
. ?( ^! X: Y/ q0 H1 K( a0 r- sCategory:
& N) B3 n3 \+ U7 V) \% oTumor Biology 0 k6 {. a. b0 }6 O- T% J! C
7 u" Y/ j. v. N0 m. k
+ E1 \9 [' D# W3 J
Meeting:( o7 d+ N+ p# R! `8 i
2011 ASCO Annual Meeting + P; {' `9 _0 G) I. K% X/ ]
. u5 F+ R2 `4 G5 d- u6 g+ t) I' v2 x) d0 z0 t# p6 S; }
Session Type and Session Title:
! `. u6 v0 J9 |6 q+ X4 OPoster Discussion Session, Tumor Biology
: d+ _- U- h! p% ]5 s
7 p0 a7 N1 _: |7 U' W$ `7 U& R
Abstract No:/ J. R% }& P4 u6 T
10517
: W+ {4 e6 l5 b2 e2 H/ Z+ {7 a+ s+ s$ r! d
9 `: E- Q$ l+ J, M( h# x/ n
Citation:
c# W3 |3 s4 z( pJ Clin Oncol 29: 2011 (suppl; abstr 10517) 8 o/ {$ M0 `/ H9 A
, K. T: O5 ]/ f; W& m" e
M" _9 ~- k$ F2 uAuthor(s):
- I+ ~ g# J1 F/ p# oJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 5 t$ y% g* m) T5 ^
8 x+ i) q) F. h' O; F) u! A; [, K$ H1 U
: t# C+ P) R% L% g8 h$ B" C( ]
* e5 Q8 a( W1 |+ F! OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
1 V- V6 T0 n8 M2 n5 W) Y
0 d, {0 u3 n1 I }* A( h! r. tAbstract Disclosures3 [! E% T- o' x5 D. ?0 _$ g- u) ]" o0 t
/ {. V; L: l' n
Abstract:4 h: x4 t5 [! W- ?
! r, T! ~5 o! S f* u! c6 Z4 q4 D1 C) a% {, h* Z9 o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 S" I! R" N& i' ^1 P+ R4 L( j& G: N8 N( l" W/ l
, m' A! L5 Z2 {& \0 y! V7 e) W |
& c, |9 L- e. c- V6 x$ S
显身卡
